Concepts (135)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anus Neoplasms | 2 | 2018 | 411 | 0.940 |
Why?
|
| Sentinel Lymph Node | 1 | 2017 | 216 | 0.510 |
Why?
|
| Melanoma | 3 | 2017 | 5317 | 0.430 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2018 | 5437 | 0.420 |
Why?
|
| Dactinomycin | 1 | 2011 | 145 | 0.410 |
Why?
|
| Preoperative Care | 2 | 2020 | 1529 | 0.380 |
Why?
|
| Pancreatectomy | 5 | 2022 | 652 | 0.350 |
Why?
|
| Chemoradiotherapy | 1 | 2018 | 1946 | 0.340 |
Why?
|
| Melphalan | 1 | 2011 | 834 | 0.330 |
Why?
|
| Lymph Nodes | 3 | 2017 | 2967 | 0.280 |
Why?
|
| Gallbladder Neoplasms | 2 | 2018 | 245 | 0.270 |
Why?
|
| Skin Neoplasms | 2 | 2011 | 4654 | 0.260 |
Why?
|
| Postoperative Complications | 4 | 2020 | 5542 | 0.250 |
Why?
|
| Carcinoma, Pancreatic Ductal | 3 | 2022 | 1724 | 0.250 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2004 | 118 | 0.240 |
Why?
|
| Tumor Burden | 2 | 2018 | 1987 | 0.200 |
Why?
|
| Pancreatic Neoplasms | 4 | 2022 | 5061 | 0.200 |
Why?
|
| Chemotherapy, Adjuvant | 6 | 2019 | 3890 | 0.190 |
Why?
|
| Neoplasm Grading | 2 | 2018 | 1742 | 0.190 |
Why?
|
| Ventilators, Mechanical | 1 | 2020 | 50 | 0.180 |
Why?
|
| Resource Allocation | 1 | 2020 | 67 | 0.180 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2004 | 384 | 0.180 |
Why?
|
| Coloring Agents | 1 | 2020 | 234 | 0.180 |
Why?
|
| Colonic Neoplasms | 2 | 2018 | 1390 | 0.180 |
Why?
|
| Indocyanine Green | 1 | 2020 | 117 | 0.180 |
Why?
|
| Lymphatic Metastasis | 4 | 2019 | 4844 | 0.170 |
Why?
|
| Neoplasm Staging | 7 | 2019 | 13658 | 0.170 |
Why?
|
| Nutrition Assessment | 1 | 2020 | 169 | 0.170 |
Why?
|
| Hyperparathyroidism, Primary | 1 | 2020 | 135 | 0.170 |
Why?
|
| Intraoperative Care | 1 | 2020 | 259 | 0.170 |
Why?
|
| Elective Surgical Procedures | 1 | 2020 | 250 | 0.170 |
Why?
|
| Parathyroidectomy | 1 | 2020 | 203 | 0.170 |
Why?
|
| Ureter | 1 | 2020 | 209 | 0.160 |
Why?
|
| Chemoradiotherapy, Adjuvant | 2 | 2019 | 565 | 0.160 |
Why?
|
| Cholecystectomy | 1 | 2018 | 107 | 0.160 |
Why?
|
| Hernia, Abdominal | 1 | 2018 | 41 | 0.160 |
Why?
|
| Aged | 17 | 2020 | 70117 | 0.150 |
Why?
|
| Thrombosis | 1 | 2004 | 781 | 0.150 |
Why?
|
| Malnutrition | 1 | 2020 | 218 | 0.150 |
Why?
|
| Anal Canal | 1 | 2018 | 238 | 0.150 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2018 | 2231 | 0.150 |
Why?
|
| Biliary Tract Surgical Procedures | 1 | 2017 | 42 | 0.150 |
Why?
|
| Retrospective Studies | 13 | 2022 | 37905 | 0.150 |
Why?
|
| Patient Care Planning | 1 | 2019 | 297 | 0.150 |
Why?
|
| Surgical Procedures, Operative | 1 | 2020 | 383 | 0.140 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2018 | 181 | 0.140 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2017 | 334 | 0.130 |
Why?
|
| Drainage | 1 | 2017 | 416 | 0.130 |
Why?
|
| Middle Aged | 15 | 2020 | 86204 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 527 | 0.120 |
Why?
|
| Quality Indicators, Health Care | 1 | 2017 | 348 | 0.120 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2017 | 690 | 0.120 |
Why?
|
| Surgical Wound Infection | 1 | 2018 | 450 | 0.120 |
Why?
|
| Hospitals | 1 | 2017 | 485 | 0.120 |
Why?
|
| Lymph Node Excision | 2 | 2018 | 1959 | 0.120 |
Why?
|
| Male | 17 | 2022 | 123000 | 0.120 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2011 | 10035 | 0.110 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2019 | 15862 | 0.110 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 860 | 0.110 |
Why?
|
| Humans | 22 | 2022 | 261506 | 0.110 |
Why?
|
| Bile Duct Neoplasms | 1 | 2017 | 493 | 0.110 |
Why?
|
| Cholangiocarcinoma | 1 | 2017 | 493 | 0.110 |
Why?
|
| Decision Making | 1 | 2020 | 1287 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 651 | 0.100 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 715 | 0.100 |
Why?
|
| Robotic Surgical Procedures | 1 | 2018 | 481 | 0.100 |
Why?
|
| Pandemics | 1 | 2020 | 1559 | 0.100 |
Why?
|
| Databases, Factual | 1 | 2018 | 2218 | 0.100 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 1 | 2011 | 169 | 0.090 |
Why?
|
| Female | 15 | 2020 | 141928 | 0.090 |
Why?
|
| Survival Rate | 3 | 2018 | 12221 | 0.090 |
Why?
|
| Rectal Neoplasms | 1 | 2018 | 1202 | 0.090 |
Why?
|
| Treatment Outcome | 5 | 2019 | 32848 | 0.090 |
Why?
|
| Laparoscopy | 1 | 2018 | 1225 | 0.080 |
Why?
|
| Neoadjuvant Therapy | 2 | 2019 | 4975 | 0.080 |
Why?
|
| Colorectal Neoplasms | 1 | 2004 | 3578 | 0.080 |
Why?
|
| Adult | 7 | 2019 | 77950 | 0.080 |
Why?
|
| Aged, 80 and over | 5 | 2020 | 29902 | 0.080 |
Why?
|
| Tissue Adhesives | 1 | 2008 | 51 | 0.080 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2012 | 600 | 0.080 |
Why?
|
| Pancreatic Fistula | 1 | 2008 | 99 | 0.070 |
Why?
|
| Genital Neoplasms, Female | 1 | 2012 | 735 | 0.070 |
Why?
|
| Drug Administration Schedule | 1 | 2011 | 3472 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 2992 | 0.060 |
Why?
|
| Ultrasonography | 1 | 2011 | 1863 | 0.060 |
Why?
|
| Length of Stay | 1 | 2011 | 1900 | 0.060 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2011 | 1415 | 0.060 |
Why?
|
| Neoplasms, Second Primary | 1 | 2012 | 1350 | 0.060 |
Why?
|
| Young Adult | 4 | 2019 | 21445 | 0.060 |
Why?
|
| Posture | 1 | 2004 | 215 | 0.060 |
Why?
|
| Cohort Studies | 3 | 2020 | 9244 | 0.050 |
Why?
|
| Proteins | 1 | 2008 | 1963 | 0.040 |
Why?
|
| Parathyroid Hormone | 1 | 2020 | 194 | 0.040 |
Why?
|
| Proportional Hazards Models | 2 | 2017 | 4988 | 0.040 |
Why?
|
| Adenocarcinoma | 1 | 2017 | 7789 | 0.040 |
Why?
|
| Colon, Ascending | 1 | 2018 | 12 | 0.040 |
Why?
|
| Neomycin | 1 | 2018 | 38 | 0.040 |
Why?
|
| Nutritional Status | 1 | 2020 | 337 | 0.040 |
Why?
|
| Colon, Sigmoid | 1 | 2018 | 42 | 0.040 |
Why?
|
| Fascia | 1 | 2018 | 68 | 0.040 |
Why?
|
| Cathartics | 1 | 2018 | 42 | 0.040 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2022 | 690 | 0.040 |
Why?
|
| Citric Acid | 1 | 2018 | 54 | 0.040 |
Why?
|
| Anastomotic Leak | 1 | 2018 | 71 | 0.040 |
Why?
|
| Operative Time | 1 | 2018 | 217 | 0.040 |
Why?
|
| Metronidazole | 1 | 2018 | 149 | 0.040 |
Why?
|
| Organometallic Compounds | 1 | 2018 | 191 | 0.040 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2020 | 605 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2020 | 6869 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2017 | 9180 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2017 | 756 | 0.030 |
Why?
|
| Incidence | 2 | 2018 | 5673 | 0.030 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2018 | 500 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2020 | 1274 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2018 | 1544 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2018 | 14889 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 2315 | 0.030 |
Why?
|
| United States | 2 | 2020 | 15433 | 0.030 |
Why?
|
| Registries | 1 | 2018 | 2170 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2017 | 851 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2012 | 11538 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 4298 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 3981 | 0.020 |
Why?
|
| Pancreaticojejunostomy | 1 | 2008 | 14 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2012 | 15694 | 0.020 |
Why?
|
| Adolescent | 2 | 2019 | 31252 | 0.020 |
Why?
|
| Mastectomy, Segmental | 1 | 2012 | 1026 | 0.020 |
Why?
|
| Antineoplastic Agents | 2 | 2019 | 14289 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 8865 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 10001 | 0.020 |
Why?
|
| Time Factors | 1 | 2018 | 12926 | 0.010 |
Why?
|
| Age Factors | 1 | 2012 | 5377 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2017 | 12873 | 0.010 |
Why?
|
| Prognosis | 1 | 2018 | 21713 | 0.010 |
Why?
|
| Risk Factors | 1 | 2012 | 17523 | 0.010 |
Why?
|